Purpose Autoimmune rheumatic diseases (ARD) are groups of diseases that are commonly associated with cardiac and pulmonary manifestations and may affect the morbidity and mortality of the patients. The study aimed to the assessment of cardiopulmonary manifestations and their correlation with the semi-quantitative scoring of high-resolution computed tomography (HRCT) in ARD patients. Methods and patients 30 patients with ARD were included in the study (mean age 42.2 ± 9.76 years) [10 patients were scleroderma (SSc), 10 patients were rheumatoid arthritis (RA), and 10 patients were systemic lupus erythematosus (SLE)]. They all met the diagnostic criteria of the American College of Rheumatology and underwent spirometry, echocardiography, and chest HRCT. The HRCT was assessed by a semi-quantitative score for parenchymal abnormalities. Correlation between HRCT lung scores and: inflammatory markers, lung volumes in spirometry, and echocardiographic indices has been performed. Results The total lung score (TLS) by HRCT was 14.8 ± 8.78 (mean ± SD), ground glass opacity score (GGO) was 7.20 ± 5.79 (mean ± SD) and fibrosis lung score (F) was 7.63 ± 6.05 (mean ± SD). TLS correlated significantly with ESR (r 0.528, p 0.003), CRP (r 0.439, p 0.015), PaO2 (r -0.395, P 0.031) FVC% (r -0.687, p 0.001), and echocardiographic Tricuspid E (r -0.370, p 0.044), Tricuspid E/è (r -0.397,p 0.03), ESPAP (r 0.459,p 0.011), TAPSE (r -0.405, p 0.027), MPI-TDI (r -0.428, p 0.018) and RV Global strain(r -0.567, p 0.001). GGO score correlated significantly with ESR (r 0.597, p 0.001), CRP (r 0.473, p 0.008), FVC% (r -0.558, p 0.001), and RV Global strain(r -0.496, p 0.005). F score correlated significantly with FVC% (r -0.397, p 0.030), Tricuspid E/è (r -0.445, p 0.014), ESPAP (r 0.402, p 0.028), and MPI-TDI (r -0.448, p 0.013). Conclusion The total lung score and GGO score in ARD were found to be consistently significantly correlated with FVC% predicted, PaO2, inflammatory markers, and RV functions. Fibrotic score correlated with ESPAP. Therefore, in a clinical setting, most clinicians who monitor patients suffering from ARD should concern with the applicability of semiquantitative HRCT scoring in clinical practice.
Purpose: Autoimmune rheumatic diseases (ARD) are groups of diseases that are commonly associated with cardiac and pulmonary manifestations and may affect the morbidity and mortality of the patients. This study aimed to the assessment of cardiopulmonary manifestations and its correlation with the semi-quantitative scoring of high-resolution computed tomography (HRCT) in ARD patients.Methods and patients: The study included 30 patients (mean age 42.2±9.76 years) diagnosed with ARD [10 patients were scleroderma (SSc), 10 patients were rheumatoid arthritis (RA), and 10 patients were systemic lupus erythematosus (SLE)]. All patients fulfilled the diagnostic criteria of the American College of Rheumatology and underwent spirometry, echocardiography, disease activity or disability scores, and chest HRCT. The HRCT was assessed by a semi-quantitative score for parenchymal abnormalities including ground glass opacity (GGO), fibrosis (F), and honeycombing (HC).Results: The total lung score by HRCT was 14.8±8.78 (mean±SD). There were statistically significant positive correlations between ESR (r =0.528, p=0.003), CRP (r=0.439, p =0.015) and ESPAP (r=0.459,p=0.011) and total lung score and significant negative correlation between PaO2 (r=-0.395, P=0.031), FVC% (r=-0.687, p=0.001), Tricuspid E(r= -0.370, p=0.044), Tricuspid E/è (r= -0.397,p=0.03), TAPSE (r= -0.405, p=0.027), MPI-TDI(r= -0.428, p=0.018) and RV Global strain(r= -0.567, p=0.001) and total lung score. There was no significant correlation between the total lung score and any of the disease scores.Conclusion: The semi-quantitative score is a reliable method that correlated with lung and RV functions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.